AbbVie’s atogepant meets primary and secondary endpoints in phase 3 trial
AbbVie said its migraine drug atogepant met primary and secondary endpoints in a phase 3 trial for preventive treatment of menstrual migraines. The study reduced migraine days by 1.2 days on average versus 0.4 days.